Mylan Announces First Approval for Estradiol Transdermal System.Business/Health Editors PITTSBURGH--(BUSINESS WIRE)--Feb. 29, 2000 Mylan Laboratories Inc. (NYSE NYSE See: New York Stock Exchange : MYL) today announced that it is the first company to receive approval from the U.S. Food and Drug Administration to manufacture and market Estradiol Transdermal System estradiol transdermal system, n brand names: Esbrand, Climera; drug class: estrogen; action: increases synthesis of deoxyribonucleic acid, ribonucleic acid, and selected proteins; decreases release of gonadotropin-releasing hormone; 0.1 mg/day, and 0.05 mg/day (Once-a-Week Formulation). These patches are the generic equivalent to Climara(R), a product of Berlex Laboratories. The product is indicated for the treatment of moderate to severe vasomotor vasomotor /vaso·mo·tor/ (-mo´tor) 1. affecting the caliber of blood vessels. 2. a vasomotor agent or nerve. va·so·mo·tor adj. symptoms associated with menopause, vulval and vaginal atrophy and the prevention of Postmenopausal Osteoporosis. This product will be manufactured by Mylan in its St. Albans, Vermont Places named St. Albans, Vermont:
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion